Advertisement
The Essential Resource for the Medical Design Engineering Community
Subscribe to MDT Magazine All

Nimodipine Oral Capsules: Medication Errors - IV Administration May Result in Death, Serious Harms

August 2, 2010 1:30 pm | by U.S. Food & Drug Administration | News | Comments

IV injection can result in cardiac arrest, severe falls in blood pressure, and other heart-related complications.

TOPICS:

Jeffrey Sprague, Founder, Vertical Research Partners LLC

August 2, 2010 10:45 am | by Ken PrewittAssociated Press | News | Comments

xfdfw BLOOMBERG-SURVEILLANC-03

Momenta's generic drug approval aids Q2 finances

August 2, 2010 10:38 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Momenta Pharmaceuticals Inc. is reporting that it narrowed its loss for the second quarter in the run up to its approval for its generic drug, enoxaparin, considered an alternative to Sanofi-Aventis’ Lovenox, an injectable drug to prevent and sometimes treat blood clots in the leg.

TOPICS:
Advertisement

New studies question vascular multiple sclerosis hypothesis and treatment

August 2, 2010 10:38 am | by EurekAlert | News | Comments

(Wiley-Blackwell) Two important new studies challenge the controversial hypothesis that venous congestion -- chronic cerebrospinal venous insufficiency (CCSVI) -- contributes to the development of multiple sclerosis. This theory has resulted in many MS patients receiving...

TOPICS:

Haemonetics lands blood management deal

August 2, 2010 10:38 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Haemonetics Corp. has formed a deal to provide its new blood management business intelligence portal, IMPACT Online, to member hospitals of Consorta Inc., a health-care group purchasing organization (GPO).

Repligen neuro research attracts major grant funding

August 2, 2010 10:37 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Waltham biopharmaceuticals firm Repligen Corp. has received three grants, totaling in excess of $6 million, to apply to its HDAC inhibitor research for neurodegenerative diseases like Friedreich’s Ataxia and Huntington’s Disease.

NeoProfen (ibuprofen lysine) Injection: Recall and Shortage - Risk of Particulate Matter

August 2, 2010 10:30 am | by U.S. Food & Drug Administration | News | Comments

Potential for particulate matter to result in serious adverse effects.

TOPICS:

Summary Box: Premiums drive Humana's 2Q growth

August 2, 2010 9:45 am | by The Associated Press | News | Comments

MEDICARE'S ADVANTAGE: Double-digit enrollment growth in lucrative Medicare Advantage plans helped lift Humana Inc.'s second-quarter profit 21 percent and the insurer raised its full-year outlook.BOTTOM LINE: The company earned $340.1 million, or $2 per share, up from $281.8 million, or $1.67 per...

Advertisement

Charles River Labs sees drop in Q2 numbers

August 2, 2010 9:41 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Just days after announcing the cancellation of its planned $1.6 billion buy of China’s WuXi PharmaTech (Cayman) Inc., Charles River Laboratories International Inc. reports that it numbers for the second quarter of 2010 were down versus the same period last year.

TOPICS:

Disparities in cardiovascular risk based more on socioeconomic status than race, ethnicity

August 2, 2010 9:41 am | by EurekAlert | News | Comments

(University of California - Los Angeles) A new study suggests that disparities in cardiovascular disease risk in the United States are due less to race or ethnicity than to socioeconomic status. The researchers found that there are large differences in risk by socioeconomic status...

TOPICS:

Dose optimization workshop helps reduce radiation dose associated with MDCT scans

August 2, 2010 9:41 am | by EurekAlert | News | Comments

(American College of Radiology / American Roentgen Ray Society) Numerous radiology practices were able to significantly reduce the radiation dose associated with multi-detector computed tomography scans by participating in a one day dose optimization workshop provided by the Royal...

TOPICS:

Insights from SUSS workshop on thin wafer handling at Semicon'West 2010

August 2, 2010 9:40 am | by I-Micronews | News | Comments

At the recent Semicon exhibition in San Francisco Suss assembled a group of partners and technical and market experts (shown below) to discuss the status of 3D IC and specifically temporary bonding and thin wafer handling.

RoundTable Healthcare Partners Portfolio Company, Aspen Surgical Products, Inc., Acquires Bard-Parker™ Surgical Blades and Scalpels Business

August 2, 2010 9:38 am | by Bio-Medicine.Org | News | Comments

LAKE FOREST, Ill. , Aug. 2 /- RoundTable Healthcare Partners ("RoundTable"), an operating-oriented private equity firm focused exclusively on the healthcare industry, announced today that its portfolio company, Aspen Surgical Products, Inc. (" Aspen "), has acquired the Bard-Parker...

TOPICS:

Haemonetics 1Q profit slips but tops expectations

August 2, 2010 7:45 am | by The Associated Press | News | Comments

Blood collection and processing systems maker Haemonetics Corp. said Monday its net income dipped 1 percent in the fiscal first quarter but still topped Wall Street expectations as strong sales of platelet disposables offset a decline in its plasma business.Haemonetics said earnings slipped to...

LifePoint Hospitals 2Q earnings climb 43 percent

August 2, 2010 6:45 am | by The Associated Press | News | Comments

Rural hospital operator LifePoint Hospitals Inc. said Monday its second-quarter net income climbed 43 percent compared to last year, when rising expenses helped knock down earnings.The Brentwood, Tenn., company said it earned $37.6 million, or 69 cents per share, in the three months that ended...

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading